Lessons from the withdrawal of rofecoxib: ***
Open Access
- 14 October 2004
- Vol. 329 (7471), 867-868
- https://doi.org/10.1136/bmj.329.7471.867
Abstract
Patients would be safer if drug companies disclosed adverse events before licensingKeywords
This publication has 11 references indexed in Scilit:
- Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugsBMJ, 2004
- Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDsAge and Ageing, 2004
- Medical journals and pharmaceutical companies: uneasy bedfellowsBMJ, 2003
- Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyPublished by Wiley ,2003
- A model for the future conduct of pharmacovigilancePharmacoepidemiology and Drug Safety, 2002
- Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?BMJ, 2002
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tractsGastroenterology, 1996
- Fatal cholestatic jaundice in elderly patients taking benoxaprofen.BMJ, 1982